After two years characterized by layoffs, pipeline reorganizations, FDA delays and clinical holds, Novavax CEO John Jacobs ...

new COVID vaccines from Pfizer-BioNTech, Moderna and Novavax are available this season to reduce the risk of hospitalization. This means adults have a choice in which COVID vaccine they receive ...

Novavax’s COVID-19 vaccine produced higher levels of neutralising antibodies than produced by recovered patients in an early trial, paving the way for a phase 3 trial and potential approval by ...

SINGAPORE: The updated JN.1 Novavax/Nuvaxovid COVID-19 vaccine will be offered under the national vaccination programme at selected Healthier SG general practitioner (GP) clinics until Apr 30.

Back in November 2023, pharmaphorum travelled to Uppsala, Sweden, for a Novavax press conference, the company celebrating a decade of doing what it does best: vaccines. From COVID-19 to malaria ...

As I have documented in some >20+ articles over ~ten years, Novavax is a struggling clinical phase pharma; it achieved ...

The Centers for Disease Control (CDC) yesterday announced that it would make 200,000 doses of a protein-based Novavax vaccine targeting the JN.1 subvariant of COVID-19 available to the public from ...

The first human bird flu death in the US has Moderna's vaccine development in focus for investors this week. Recently, Zacks.com users have been paying close attention to Novavax (NVAX).

Novavax, Inc. (NYSE:NVAX) is a leading biotechnology company dedicated to the discovery, development, and commercialization of innovative vaccines to prevent serious infectious diseases.

Novavax shares are trading lower by 9.8% during Monday's session. Shares of vaccine stocks are trading lower after Moderna issued 2025 revenue guidance below analyst estimates. Novavax shares ...

Moderna won an agreement for its Covid vaccines in Europe on Friday, but Moderna stock reversed its early gains. The average of price targets set by Wall Street analysts indicates a potential upside ...